Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Drilon

Showing results (81-90 of 268) with videos related to

Pageof 27
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with SmokingMaria E Arcila, Alexander Drilon, Brooke E Sylvester, et al.
JCO Precision Oncology|June 1, 2023
Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK InhibitorsMonica F Chen, Soo-Ryum Yang, Jinru Shia, et al.
American Journal of Surgery|March 12, 2023
Trends in location of death for individuals with metastatic lung cancer in the United StatesUrvish Jain, Bhav Jain, Edward Christopher Dee, et al.
Lung Cancer (Amsterdam, Netherlands)|October 16, 2021
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancersMartin Gutierrez, Robin Guo, Giuseppe Giaccone, et al.
Clinical Lung Cancer|January 20, 2024
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung CancerYun Fan, Alexander Drilon, Chao-Hua Chiu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Pageof 27

Showing results (81-90 of 268) with videos related to

Sort By:
Pageof 27
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 30, 2014
MAP2K1 (MEK1) Mutations Define a Distinct Subset of Lung Adenocarcinoma Associated with SmokingMaria E Arcila, Alexander Drilon, Brooke E Sylvester, et al.
JCO Precision Oncology|June 1, 2023
Response to Repotrectinib After Development of <i>NTRK</i> Resistance Mutations on First- and Second-Generation TRK InhibitorsMonica F Chen, Soo-Ryum Yang, Jinru Shia, et al.
American Journal of Surgery|March 12, 2023
Trends in location of death for individuals with metastatic lung cancer in the United StatesUrvish Jain, Bhav Jain, Edward Christopher Dee, et al.
Lung Cancer (Amsterdam, Netherlands)|October 16, 2021
Phase 1 multicenter study of the HSP90 inhibitor SNX-5422 plus carboplatin and paclitaxel in patients with lung cancersMartin Gutierrez, Robin Guo, Giuseppe Giaccone, et al.
Clinical Lung Cancer|January 20, 2024
Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung CancerYun Fan, Alexander Drilon, Chao-Hua Chiu, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 16, 2015
Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitorsMonika A Davare, Nadeem A Vellore, Jacob P Wagner, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 4, 2015
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung AdenocarcinomasJuliana Eng, Kaitlin M Woo, Camelia S Sima, et al.
Cancer|February 27, 2016
Beyond the dose-limiting toxicity period: Dermatologic adverse events of patients on phase 1 trials of the Cancer Therapeutics Evaluation ProgramAlexander Drilon, Anne A Eaton, Katja Schindler, et al.
JCO Precision Oncology|September 11, 2020
Larotrectinib Demonstrates CNS Efficacy in TRK Fusion-Positive Solid TumorsEzra Y Rosen, Alison M Schram, Robert J Young, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated ToxicitiesAnne Eaton, Alexia Iasonos, Mrinal M Gounder, et al.
Pageof 27